New Research Highlights Role of Genetics in Obesity Drug Outcomes

Recent scientific findings suggest that an individual’s genetic makeup may significantly influence how they respond to GLP-1-based weight-loss medications.

A study conducted by 23andMe highlights that certain genetic variants can affect both the effectiveness of these drugs and the likelihood of side effects. These insights could pave the way for more personalized and precise treatment strategies in obesity and diabetes care.

Genetic Factors Influence Weight Loss Outcomes

Role of GLP1R Gene Variants

The study, involving nearly 28,000 participants, found that mutations in the GLP1R gene—responsible for encoding the protein targeted by GLP-1 drugs—play a role in determining treatment outcomes.

• Individuals with one copy of the variant lost an average of 1.7 pounds (0.76 kilograms) more over eight months
• Those with two copies lost approximately 3.3 pounds more compared to non-carriers

Modest but Significant Impact

Although the genetic influence on weight loss was relatively small, researchers emphasized its statistical significance. The findings reinforce the idea that even subtle genetic differences can shape how patients respond to medications.

Genetic Links to Side Effects

GLP1R and GIPR Mutations

The study also identified a connection between genetic variants and side effects such as nausea and vomiting. Mutations in both the GLP1R gene and the GIPR gene—linked to insulin regulation and energy metabolism—were associated with these adverse reactions.

Specific Impact of Tirzepatide

The side-effect association with GIPR mutations was particularly observed in patients using Tirzepatide.

• Individuals carrying the variant were 83% more likely to experience vomiting
• The drug is marketed as Mounjaro for diabetes and Zepbound for weight loss

Implications for Precision Medicine

Toward Personalised Treatment

Researchers noted,
“These findings provide direct genetic evidence that variation in the drug-target genes contributes to inter-person variability in response and lay the foundation for precision medicine approaches in the treatment of obesity,”

This suggests that in the future, doctors may tailor obesity treatments based on a patient’s genetic profile, improving both safety and effectiveness.

Cardiovascular Benefits Beyond Weight Loss

Study on Semaglutide and Heart Health

Another study explored the cardiovascular benefits of GLP-1 drugs, particularly Semaglutide, sold as Ozempic and Wegovy.

Researchers analyzed 47,199 patients with cardiovascular disease over a period of up to two years.

Key Findings

• Higher doses of the drug were linked to greater weight loss
• Patients receiving higher doses showed reduced risks of:
  • Death from any cause
  • Heart attack and stroke
  • Heart failure and valve issues

Interestingly, these cardiovascular benefits were not directly linked to the amount of weight lost, suggesting separate mechanisms at play.

Exploring the Drug’s Mechanism

Potential Direct Impact on the Heart

The study found that GLP-1 receptors are highly present not only in the pancreas but also in the heart. This opens up the possibility that these drugs may directly influence heart function.

Study leader Venky Soundararajan noted,
“All the focus has been on the pancreas but… is it possible that this medicine is directly acting in the heart?”

He added,
“It’s purely a hypothesis,”
“But we can say at this point that heart benefits are not directly correlated to weight loss, and there is enough molecular data to warrant actual experiments in the heart to begin to understand what the drug does.”

Breakthrough in Genetic Research Beyond Obesity

Single DNA Mutation Alters Development

In a separate study, scientists demonstrated how a tiny genetic mutation can dramatically alter biological development. By introducing a mutation in a non-coding DNA region called Enh13, researchers triggered sex reversal in mice embryos.

Importance of Non-Coding DNA

The mutation activated the Sox9 gene, leading to male development in genetically female (XX) embryos. This finding highlights the critical role of non-coding DNA, which makes up about 98% of the genome.

Nitzan Gonen stated,
“shows that non-coding DNA can have a profound effect on development and disease,”

Co-author Elisheva Abberbock added,
“Our findings show that it is not enough to look only at genes,”
“Important disease-causing mutations may also lie in the non-coding genome, in DNA regions that control gene activity,”

Conclusion

The latest research underscores the growing importance of genetics in modern medicine. From influencing the effectiveness and side effects of GLP-1 weight-loss drugs to revealing new insights into cardiovascular benefits and genetic development, these findings mark a significant step toward personalized healthcare.

As scientists continue to explore the complex relationship between genes and treatment outcomes, the future of medicine is likely to become increasingly tailored to individual patients. While more research is needed, especially in understanding long-term effects and mechanisms, these studies highlight the transformative potential of precision medicine in tackling obesity, diabetes, and beyond.